- The Onkimmune business model is focused on designing products to treat specific cancers and to move them through the development process and into the clinic where it will demonstrate the safety and efficacy of each cell product.
- Onkimmune plans to partner many of its cell products to pharmaceutical companies with proven late stage clinical development and commercial expertise in the field of oncology
- The company also plans to retain certain rights to develop its own products, thus capturing both short and long term value for its investors
- If you are interested in learning more, please click on the “Contact” button
2nd (Cause of death globally – 1 in 6 deaths are due to cancer)1
Billion $ (the global oncology market by 2022)
$1.2 Trillion (Economic cost of cancer today)1
100 (there are over 100 types of cancer)1